A comprehensive and detailed guide on ‘Drug Interactions with Tirzépatide: A Comprehensive Guide’: sourced medical information, practical recommendations, and expert advice for patients on GLP-1 treatment. Understanding the stakes The topic addressed in this article – drug interactions with tirzépatide: a comprehensive guide – is a major concern for … Read more
Comprehensive and detailed guide on ‘Tirzépatide and Chronic Kidney Disease: Précautions for Use’: sourced medical information, practical recommendations, and expert advice for patients undergoing GLP-1 treatment. Understanding the Stakes The topic addressed in this article – tirzépatide and chronic kidney disease: précautions for use – is a major concern for … Read more
Tirzépatide significantly improves the lipid profile: lowering LDL, reducing triglycerides, and increasing HDL. Impact of tirzépatide on LDL cholestérol Tirzépatide reduces LDL-cholestérol by 5 to 10% on average in clinical trials. Although this reduction is modest compared to statins, it adds to the effects of the latter. … Read more
Guide to understanding and interpreting your blood test results during tirzepatide treatment: blood glucose, lipids, liver, kidneys, and deficiencies. Glycemic markers Under tirzepatide, glycemic markers show favorable changes. Fasting blood glucose (normal: 0.70 to 1.10 g/L) decreases thanks to the drug’s action on insulin secretion and sensitivity … Read more
Tirzepatide profoundly transforms the relationship with food. From constant ‘food noise’ to an unexpected mental silence, this metamorphosis can be liberating but also destabilizing. Understanding these changes helps integrate them serenely. Before tirzepatide: omnipresent food For many patients with obesity, food occupies a disproportionate place in their mental space. … Read more
Diarrhea and constipation are the most common digestive issues with tirzepatide. Here’s how to manage them daily. Bowel transit disorders are the second most frequent side effect with Mounjaro, after nausea. Approximately 16 to 23% of patients report episodes of diarrhea and 11 to 17% suffer from constipation. These two … Read more
The SURMOUNT-Jr study paves the way for the treatment of severe obesity in adolescents with tirzepatide, showing superior results to any existing treatment. Pediatric obesity is a global public health crisis. In France, approximately 18% of children and adolescents are overweight or obese, with major physical and psychological consequences. The SURMOUNT-Jr study, … Read more
Discontinuing tirzepatide leads to weight regain in the majority of patients. Here are the scientific data and strategies to limit this phenomenon. One of the most important questions for patients on Mounjaro is: what happens when treatment is stopped? Data from the SURMOUNT-4 study and observational studies provide … Read more
Tirzepatide could become the first effective drug treatment for non-alcoholic steatohepatitis (NASH), a disease affecting millions of French people. Non-alcoholic fatty liver disease (NAFLD), and its progressive form, steatohepatitis (NASH), represent one of the greatest silent epidemics of the 21st century. In France, it is estimated that 18 to 25% of … Read more
With tirzepatide, weight loss isn’t just fat. Understanding body composition is essential to optimize your treatment. One of the major concerns during rapid weight loss is the loss of muscle mass. With GLP-1 agonists like tirzepatide, this issue is even more relevant as weight loss … Read more
The SURMOUNT-3 and SURMOUNT-4 studies answer the crucial question: what happens long-term with tirzepatide? One of the main challenges of anti-obesity treatments is long-term weight loss maintenance. The SURMOUNT-3 and SURMOUNT-4 studies, published in 2023 and 2024, provide essential data on the durability … Read more
The SURMOUNT-1 study laid the scientific foundation for the use of tirzepatide in obesity. A detailed analysis of the game-changing results. Published in the New England Journal of Medicine in July 2022, the SURMOUNT-1 study is the pivotal clinical trial that led to the authorization of tirzepatide (Zepbound) for the treatment of obesity. With 2,539 participants … Read more